



NextPharma Technologies US Subsidiary Announces Outsourcing Agreement With Advantar Laboratories Inc.

Surrey, UK, 16th March 2009 - NextPharma Technologies, a leading provider of pharmaceutical product development, contract manufacturing, cold chain and distribution outsourcing services, is pleased to announce that its subsidiary in the US (Bioserv Corporation) has entered in to a non-exclusive outsourcing agreement with Advantar Laboratories Inc. a provider of high quality contract laboratory services to small and mid-sized companies engaged in drug development.

Under this agreement NextPharma will collaborate with Advantar to provide Advantar's customers with aseptic and non-aseptic fill and finish services including lyophilization, packaging, labeling, storage and shipment of clinical materials to clinical sites. Advantar will collaborate with NextPharma's customers based in the United States to provide NextPharma's customers with analytical services support including methods development, in process testing and finished product testing of sterile and non-sterile products.

Sean Marett, Managing Director, Product Development Services commented "This opportunity to work with Advantar as an outsourcing partner is mutually beneficial as our capabilities align well with theirs and this agreement has the potential to provide a wealth of synergistic benefits to both parties." Richard Kenley, President and CEO – Advantar Laboratories commented "We are pleased to have this opportunity to collaborate with NextPharma in supporting their needs for analytical services."

NextPharma develops, manufactures, packages, and distributes a broad range of products and formulations for its customers including solids, liquids and semi-solid dosage forms, antibiotics, hormones and controlled release medicines. It has an established leadership position in the high technology area of injectables manufacturing (lyophilized and liquid fill), with particular expertise in product development and manufacture of oncology medicines.

Advantar Laboratories Inc. offers expertise in preformulation and formulation development, analytical method development, validation, quality control, stability testing, toxicology test article preparation and testing, and other technical support needed in the development of pharmaceutical products.

-Ends-

Contact:

Bill Wedlake

Chief Executive Officer
NextPharma Technologies Holding Limited
Tel +44 (0) 1483 479 121

Notes to Editors:

About NextPharma

NextPharma Technologies, headquartered in the UK and founded in 2000, is a world class outsourcing partner to the pharmaceutical and biotechnology industry.

We offer a full range of services from early phase product development, through clinical trial packaging (Phases I through III) to high volume commercial manufacturing. We are a world leader in lyophilization, sterile fill finish and pellet technologies and in specialist product manufacturing including cytotoxics, hormones, penicillins, cephalosporins and controlled drugs. Our sterile development and production offers a full range of drug delivery technologies including pre-filled syringes, vials and ampoules. Additionally we have significant expertise in paediatric drug formulation, development and manufacture.

We operate globally with seven product development centres, seven manufacturing plants and six temperature controlled storage and distribution sites across Europe and North America, supplying customers in North America, Europe and Japan.

We have 1,200 employees dedicated to serving over 200 customers world wide and a customer base, which includes many of the world's leading pharmaceutical, specialty pharma and biotech companies.

We have a proven track record in almost all pharmaceutical technologies and product forms and in addition to the specialist areas above have capabilities in solids, semi-solids, liquids, sprays and dry dosage form technologies.

All of our sites are either FDA inspected, in the process of upgrade for inspection or targeted for upgrade for inspection.